Baselight
Sign In
YesterdayJun 12Jun 11Jun 10Jun 9Jun 8Jun 7Jun 6Jun 5Jun 4Jun 3Jun 2Jun 1May 31May 30May 29May 28May 27May 26May 25May 24May 23May 22May 21May 20May 19May 18May 17May 16May 15May 14May 13May 12May 11May 10May 9May 8May 7May 6May 5May 4May 3May 2May 1Apr 30Apr 29Apr 28Apr 27Apr 26Apr 24Apr 22Apr 21Apr 20Apr 19Apr 18Apr 17

Stocks

June 3, 2026

Anomaly01STOCKS

Laser Photonics Surges 160% on Military Technical Review Selection for Laser Shield System

  • Laser Photonics shares surged after its Laser Shield Anti-Drone system was selected for a technical review program by the U.S. Department of War.
  • The stock jumped 160.78% to close at $2.42 on June 2, with trading volume exploding to 275.71 million shares—224.5 times its 20-day average.
  • The selection represents an early-stage evaluation milestone; advancing beyond the technical exchange may lead to follow-on prototyping and experimentation.
Laser Photonics Surges 160% on Military Technical Review Selection for Laser Shield System
Outlier02STOCKS

Fulcrum Therapeutics Plunges 51% After Discontinuing Lead Sickle Cell Drug Over FDA Concerns

  • Fulcrum Therapeutics suffered a massive selloff after halting its lead clinical program, pociredir, due to FDA concerns over malignancy risks.
  • The stock plummeted 51.09% to close at $3.14 on June 2, while trading volume skyrocketed to 52.7 times its 20-day average.
  • The discontinuation of its primary clinical asset represents a severe setback for the company's pipeline and raises doubts about its long-term viability.
Fulcrum Therapeutics Plunges 51% After Discontinuing Lead Sickle Cell Drug Over FDA Concerns
Outlier03STOCKS

Abivax Suffers Severe 44% Drop on Ulcerative Colitis Trial Cancer Reports

  • Abivax shares fell sharply following reports of non-melanoma skin cancers and other malignancies in its pivotal obefazimod study.
  • The stock declined 44.10% to close at $72.50 on June 2, on volume that spiked to 11.6 times its 20-day average.
  • Safety concerns in late-stage clinical trials can derail drug approvals, threatening the commercial future of Abivax's lead therapeutic candidate.
Abivax Suffers Severe 44% Drop on Ulcerative Colitis Trial Cancer Reports
Trend Shift04STOCKS

Legend Biotech Surges 42% to Break Losing Streak on 100% Lymphoma Trial Success

  • Legend Biotech shares rallied strongly after the company announced a 100% response rate in a Phase 1 trial for its experimental lymphoma treatment.
  • The stock soared 42.22% to close at $36.28 on June 2, breaking a four-day losing streak on 5.9 times its average trading volume.
  • Perfect efficacy results in early-stage trials bolster confidence in the company's next-generation CAR-T platform and its potential to treat aggressive cancers.
Legend Biotech Surges 42% to Break Losing Streak on 100% Lymphoma Trial Success
Divergence05STOCKS

Lowe's Hits 52-Week Low as Analysts Cut Quarterly Earnings Estimates

  • Lowe's Companies fell to a new 52-week low as analysts cut their earnings expectations amid persistent housing market headwinds.
  • The stock touched an intraday low of $204.51 on June 2, facing 27 downward EPS revisions and zero upward revisions over the last week.
  • The downward revisions follow cautious forward guidance, reflecting concerns about high interest rates and cooling home improvement demand.
Lowe's Hits 52-Week Low as Analysts Cut Quarterly Earnings Estimates
Trend Shift06STOCKS

MongoDB Surges 37% in Three Days on Strong Earnings Beat and Wall Street Upgrades

  • MongoDB shares staged a massive multi-day rally fueled by a strong Q1 earnings beat and subsequent price target upgrades from major banks.
  • The stock surged 37.10% over three days to close at $398.46 on June 2, supported by 31 upward EPS revisions for the current quarter.
  • The sharp rebound reflects renewed investor confidence in MongoDB's cloud database platform and AI-driven growth prospects.
MongoDB Surges 37% in Three Days on Strong Earnings Beat and Wall Street Upgrades

Share link

Anyone who has the link will be able to view this.